多肽CRDMO平台
目录肽
大奖888生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
LHRH-017B
Nafarelin
Pyr-His-Trp-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH2\nAcetate salt \n\n
Pyr-His-Trp-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH2\nAcetate salt \n\n
Size：25
P1(RMB)：942
MW：1322.49
One letter sequence：Pyr-HWSY-D-2-Nal-LRPG-NH2
Molecular Formula：C66H83N17O13
Description：Nafarelin is a synthetic decapeptide agonist of the luteinizing hormone-releasing hormone (LHRH) which is approximately 200 times more potent than the natural peptide. Like LHRH nafarelin stimulates the release of the gonadotrophins luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary which in turn results in an initial increase of testosterone and estradiol synthesis. Continuous administration of LHRH or one of its analogs causes a sustained down-regulation of circulating LH and FSH levels leading to a suppression of testicular and ovarian steroidogenesis. Currently, nafarelin is indicated for the treatment of endometriosesis and for the use in reproductive medicine.
Literature Reference：P.Chrisp and K.L.Goa, Drugs, 39, 523 (1990)\nT.Mizutani et al., Int. J. Fertil. Menopaus. Stud., 40, 106 (1995)\nMerck Index, 14th ed., No. 6351, (2006)
Cas：76932-56-4
P1(RMB)：942
MW：1322.49
One letter sequence：Pyr-HWSY-D-2-Nal-LRPG-NH2
Molecular Formula：C66H83N17O13
Description：Nafarelin is a synthetic decapeptide agonist of the luteinizing hormone-releasing hormone (LHRH) which is approximately 200 times more potent than the natural peptide. Like LHRH nafarelin stimulates the release of the gonadotrophins luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary which in turn results in an initial increase of testosterone and estradiol synthesis. Continuous administration of LHRH or one of its analogs causes a sustained down-regulation of circulating LH and FSH levels leading to a suppression of testicular and ovarian steroidogenesis. Currently, nafarelin is indicated for the treatment of endometriosesis and for the use in reproductive medicine.
Literature Reference：P.Chrisp and K.L.Goa, Drugs, 39, 523 (1990)\nT.Mizutani et al., Int. J. Fertil. Menopaus. Stud., 40, 106 (1995)\nMerck Index, 14th ed., No. 6351, (2006)
Cas：76932-56-4
